AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...
Psychosis affects one's physical, psychological, social, and existential health. Mental health recovery often involves a ...
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...
GlobalData on MSN6d
Teva’s long-lasting schizophrenia injectable shines in Phase IIIData presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...
Medpage Today on MSN8d
Adjunctive Antipsychotic Helps Ease Symptoms of DepressionAddition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a ...
Phase 3 trial results show Teva's TEV-'749 improves social functioning in adults with schizophrenia without post-injection ...
Lyu X, Li Z, Chen S, et al. Transcranial direct current stimulation improves tardive dyskinesia in long-term hospitalized patients with chronic schizophrenia. Clin Neurophysiol. 2024;166:20-30. doi:10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback